OliX secures Australian ethics approval for OLX10212 Phase 2a trial
OliX said its OLX10212 macular degeneration treatment received approval for a Phase 2a trial in Australia from the Bellberry Human Research Ethics Committee on Oct. 30, 2026.
OliX said its OLX10212 macular degeneration treatment received approval for a Phase 2a trial in Australia from the Bellberry Human Research Ethics Committee on Oct. 30, 2026.